NewsNovo
Pfizer topped its quarterly earnings estimates and raised the low end of its full-year revenue guidance, with the lift driven by products outside its Covid portfolio.
The complication sits right next to the headline: the company also cut its full-year Covid product revenue expectation to $4 billion, down from around $5 billion previously, putting the non-pandemic business under more pressure to hold the line.
What the guidance raise signals Raising the low end of full-year guidance, rather than the top end, narrows the range without committing to an unconstrained upgrade.
The move reflects genuine confidence in the non-Covid business, which came in above estimates for the quarter, but it stops short of a broad upward revision. Management is saying the floor is higher.
Keep reading